NCT04189549 (Pre-SEPSIS) is a clinical trial of CNA Rapid Sepsis Dx in Sepsis, sponsored by Robert Ehrman.

Who is sponsoring NCT04189549?

NCT04189549 is sponsored by Robert Ehrman.

What drugs are being tested in NCT04189549?

Interventions in NCT04189549: CNA Rapid Sepsis Dx.

Is NCT04189549 still recruiting?

NCT04189549 is currently status unknown. Last updated 6 December 2019.

Last reviewed 2019-12-06 · How we verify

NCT04189549: Pre-SEPSIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preclinical Detection of Sepsis Early in Hospitalized Patients Following Surgery, Injury or Severe Illness

Status unknown Last updated 6 December 2019

What this trial tests

trial testing CNA Rapid Sepsis Dx in Sepsis in 2,000 participants. Status unknown.

Timeline

9 December 2019

Primary endpoint
1 November 2020

30 April 2021

Quick facts

Lead sponsor	Robert Ehrman
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	9 December 2019
Primary completion	1 November 2020
Estimated completion	30 April 2021
Sites	5 locations across United States

Drugs / interventions tested

CNA Rapid Sepsis Dx

Conditions studied

Sepsis — all drugs for Sepsis →

Sponsor

Robert Ehrman

Who can join

18 and older, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical study is to evaluate a novel biomarker - CNA Rapid Sepsis Dx - to predict the development of sepsis in patients admitted to the hospital with non-sepsis conditions. Using circulating cell-free DNA (cfDNA) in the blood stream, it has been demonstrated to detect infection response days before clinical evidence of sepsis manifests. The hypothesis is that blood biomarkers drawn daily in the hospital will identify patients who develop sepsis within seven days of hospital presentation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current Trends in Cell-Free DNA Applications. Scoping Review of Clinical Trials.
Stawski R, Stec-Martyna E, Chmielecki A, Nowak D, et al · · 2021 · cited 20× · PMID 34571783 · DOI 10.3390/biology10090906

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04189549 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Robert Ehrman
Last refreshed: 6 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04189549.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing